New Technologies For Hierarchial Shotgun Sequencing Of Recalcitrant And Repetitive DNA
Funder
National Health and Medical Research Council
Funding Amount
$79,750.00
Summary
Many repetitive regions of genomes are difficult to sequence and to assemble. �Sequencing Aided by Mutation� (SAM) is a new sequencing technology, which overcomes many of the difficulties that hinder current sequencing methods. SAM involves forming randomly mutated copies of the target DNA. These copies can then be sequenced and new mathematical tools permit the original target sequence to be revealed from the mutant copies. Here the technology will be developed to aid sequencing of long repetit ....Many repetitive regions of genomes are difficult to sequence and to assemble. �Sequencing Aided by Mutation� (SAM) is a new sequencing technology, which overcomes many of the difficulties that hinder current sequencing methods. SAM involves forming randomly mutated copies of the target DNA. These copies can then be sequenced and new mathematical tools permit the original target sequence to be revealed from the mutant copies. Here the technology will be developed to aid sequencing of long repetitive DNA fragments in genomes.Read moreRead less
This research will advance the development of a novel vaccine strategy based on duck hepatitis B virus-like particles (VLPs). These VLPs can be engineered to contain parts of other viruses such as Hepatitis C, HIV or Measles, and have been shown to produce strong antibody responses in mice. Detailed information on the cellular and antibody responses to these VLP vaccines will be aligned with GLP processes to support future clinical trials in man, providing support for the development of urgently ....This research will advance the development of a novel vaccine strategy based on duck hepatitis B virus-like particles (VLPs). These VLPs can be engineered to contain parts of other viruses such as Hepatitis C, HIV or Measles, and have been shown to produce strong antibody responses in mice. Detailed information on the cellular and antibody responses to these VLP vaccines will be aligned with GLP processes to support future clinical trials in man, providing support for the development of urgently needed vaccines against a range of infectious diseases.Read moreRead less
Neuropathic Pain Drugs Based On The Endogenous Opioid Peptide Endomorphin 1.
Funder
National Health and Medical Research Council
Funding Amount
$209,470.00
Summary
We have developed a new pain drug based on the natural pain killing opioid peptide, Endomorhin 1. The new drug exhibits activity similar to morphine and gabapentin against neuropathic pain in animals but seems to act through a different mechanism. We will complete our preclinical investigation of this compound by assessing its side effect profile and tolerence inducing properties in animals. We will also continue our development of an orally active analogue of this important peptide.
Identification And Characterisation Of Amplified Oncogenes In Liposarcoma
Funder
National Health and Medical Research Council
Funding Amount
$354,293.00
Summary
Liposarcoma is the commonest single subtype of sarcomas, a group of cancers that disproportionately affects the young. The overall mortality for liposarcomas is approximately 50%. Chemotherapy may temporarily controlling disease in under a third of patients, but is toxic and cannot achieve cure. We have identified new potential therapeutic targets, and aim to develop these in the clinic.
Antitumour Efficacy Of TRAIL: An Immunotherapeutic Approach For The Treatment Of Skeletal Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$459,034.00
Summary
The most serious clinical problem with patients with solid tumours is metastasis to bone, which leads to complications that can cause erosion of the patient's quality of life, and eventually death. TRAIL is a new cancer therapeutic that selectively kills cancer cells while sparing normal cells. The use of TRAIL agonistic antibodies that do not bind OPG and have increased serum half life offers an exciting approach for the treatment of skeletal malignancies that is non toxic and safe.
A multi-agent system for stakeholder management in off-site construction. This project aims to investigate a socio-technology model for stakeholders and informatics to improve off-site construction (OSC) productivity in infrastructure construction. A multi-agent system for OSC could drive down cost, but requires highly integrated collaboration among stakeholders. The project’s quantitative approaches include large-scale social network analysis, multi-agent consensus modelling and an optimisation ....A multi-agent system for stakeholder management in off-site construction. This project aims to investigate a socio-technology model for stakeholders and informatics to improve off-site construction (OSC) productivity in infrastructure construction. A multi-agent system for OSC could drive down cost, but requires highly integrated collaboration among stakeholders. The project’s quantitative approaches include large-scale social network analysis, multi-agent consensus modelling and an optimisation algorithm for collaborative planning. The project outcomes are expected to secure long-term economic benefits by enhancing performance in complex projects.Read moreRead less